New hope for pancreatic cancer: drug combo trial launches

NCT ID NCT07259317

Recruiting now Disease control Sponsor: Corcept Therapeutics Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 24 times

Summary

This study tests a new drug called relacorilant combined with two standard chemotherapy drugs for people with advanced pancreatic cancer that has spread. The goal is to see if the combination can help control the cancer longer and improve survival. About 60 participants will receive the treatment, and researchers will monitor how well it works and any side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Site 01
RECRUITING

San Antonio, Texas, 78229, United States
Site 02
RECRUITING

Scottsdale, Arizona, 85258, United States
Site 03
RECRUITING

Grand Rapids, Michigan, 49503, United States
Site 04
RECRUITING

Los Angeles, California, 90025, United States
Site 05
RECRUITING

Lake Success, New York, 11042, United States
Site 06
RECRUITING

Atlanta, Georgia, 30322, United States
Site 07
RECRUITING

Shirley, New York, 11967, United States
Site 08
RECRUITING

Albany, New York, 12206, United States
Site 09
RECRUITING

Nashville, Tennessee, 37203, United States
Site 10
RECRUITING

East Brunswick, New Jersey, 08816, United States

Conditions

Explore the condition pages connected to this study.

ADENOCARCINOMA CARCINOMA, PANCREATIC DUCTAL